Apalutamide for prostate cancer: Multicentre and multidisciplinary real‐world study of 227 patients
Cancer Medicine · 2023
DOI: 10.1002/cam4.6769 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Julián Córdoba Sánchez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Uro-Oncology Unit, Hospital Clínic, Barcelona, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of apalutamide prostate cancer compared to the pivotal trials patients and to identify the first subsequent therapy in a real‐world setting.
Methods
The study is prospective and observational based on real‐world evidence, performed by different medical disciplines and eight academics centres around Barcelona, Spain. It included all patients with metastatic hormone‐sensitive prostate cancer (mHSPC) and high‐risk non‐metastatic castration‐resistant prostate cancer (nmCRPC) treated with apalutamide from June 2018 to December 2022.
Results
Of 227 patients treated with apalutamide, 10% had ECOG‐PS 2, and 41% were diagnosed with new‐generation imaging. In the mHSPC group (209 patients), 75 years was the median age, 53% had synchronous metastases, and 22% were M1a. In the nmCRPC (18 patients), 82 years was the median age, and 81% ≤6 months had PSA doubling time. Patients achieved PSA90 in 92% of mHSPC and 50% of nmCRPC and PSA ≤0.2 in 71% of mHSPC and 39% of nmCRPC. Treatment‐related adverse events occurred in 40.1% of mHSPC and 44.4% of nmCRPC. After discontinuation of apalutamide due to disease progression, 54.5% in mHSPC and 75% in nmCRPC started chemotherapy, while after discontinuation because of adverse events, 73.3% in mHSPC and 100% in nmCRPC continued with other hormonal‐therapies.
Conclusions
The efficacy and safety of apalutamide were similar to that described in the pivotal trials, despite including an older and more comorbid population. Usually, subsequent therapies after apalutamide differed depending on the reason for discontinuation: by disease progression started chemotherapy and by adverse events hormonal sequencing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Uro-Oncology Unit, Hospital Clínic, Barcelona, Spain.
- Urology Department, Hospital Belltvige, Barcelona, Spain.
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain.
- Urology Department, Hospital Val D'Hebron, Barcelona, Spain.
- Medical Oncology Department, Hospital Vall D'Hebron, Barcelona, Spain.
- Urology Department, Consorci Sanitari de Terrassa, Terrassa.
ORCID-Profile: Julián Córdoba Sánchez
Zitieren
APA
Sánchez, J. C., Picola, N., Rodriguez-Vida, A., Costa, M., Castañeda, D. M., Márquez, M. P., Rodriguez, J. M., Gaya, J. M., Bravo, A., Buisan, O., Servian, P., Suarez, J. F., Felip, M. M., Caparrós, M. J. R., Asensio, A. A., & Vilaseca, A. (2023). Apalutamide for prostate cancer: Multicentre and multidisciplinary real‐world study of 227 patients. Cancer Medicine. https://doi.org/10.1002/cam4.6769
Vancouver
Sánchez JC, Picola N, Rodriguez-Vida A, Costa M, Castañeda DM, Márquez MP, et al. Apalutamide for prostate cancer: Multicentre and multidisciplinary real‐world study of 227 patients. Cancer Medicine. 2023. doi:10.1002/cam4.6769
BibTeX
@article{Snchez2023,
author = {Sánchez, Julián Córdoba and Picola, Natalia and Rodriguez-Vida, Alejo and Costa, Marc and Castañeda, David Marmolejo and Márquez, Meritxell Pérez and Rodriguez, Jesús Muñoz and Gaya, J M and Bravo, Alejandra and Buisan, Oscar and Servian, Pol and Suarez, Jose Francisco and Felip, Mireia Musquera and Caparrós, Maria Jose Ribal and Asensio, Antonio Alcaraz and Vilaseca, Antoni},
title = {Apalutamide for prostate cancer: Multicentre and multidisciplinary real‐world study of 227 patients},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6769}
}
EUVIMED